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Abstract
Background: Diabetic retinopathy (DR) is classically defined as a microvasculopathy that primarily affects the small
blood vessels of the inner retina as a complication of diabetes mellitus (DM).It is a multifactorial disease with a
strong genetic component. The aim of this study is to investigate the association of a set of nine candidate genes
with the development of diabetic retinopathy in a South Indian cohort who have type 2 diabetes mellitus (T2DM).
Methods: Seven candidate genes (RAGE, PEDF, AKR1B1, EPO, HTRA1, ICAM and HFE) were chosen based on reported
association with DR in the literature. Two more, CFH and ARMS2, were chosen based on their roles in biological
pathways previously implicated in DR. Fourteen single nucleotide polymorphisms (SNPs) and one dinucleotide
repeat polymorphism, previously reported to show association with DR or other related diseases, were genotyped in
345 DR and 356 diabetic patients without retinopathy (DNR). The genes which showed positive association in this
screening set were tested further in additional sets of 100 DR and 90 DNR additional patients from the Aravind Eye
Hospital. Those which showed association in the secondary screen were subjected to a combined analysis with the
100 DR and 100 DNR subjects previously recruited and genotyped through the Sankara Nethralaya Hospital, India.
Genotypes were evaluated using a combination of direct sequencing, TaqMan SNP genotyping, RFLP analysis, and
SNaPshot PCR assays. Chi-square and Fisher exact tests were used to analyze the genotype and allele frequencies.
Results: Among the nine loci (15 polymorphisms) screened, SNP rs2070600 (G82S) in the RAGE gene, showed
significant association with DR (allelic P = 0.016, dominant model P = 0.012), compared to DNR. SNP rs2070600
further showed significant association with DR in the confirmation cohort (P = 0.035, dominant model P = 0.032).
Combining the two cohorts gave an allelic P < 0.003 and dominant P = 0.0013). Combined analysis with the
Sankara Nethralaya cohort gave an allelic P = 0.0003 and dominant P = 0.00011 with an OR = 0.49 (0.34 - 0.70) for
the minor allele. In HTRA1, rs11200638 (G>A), showed marginal significance with DR (P = 0.055) while rs10490924
in LOC387715 gave a P = 0.07. No statistical significance was observed for SNPs in the other 7 genes studied.
Conclusions: This study confirms significant association of one polymorphism only (rs2070600 in RAGE) with DR in
an Indian population which had T2DM.
Background
Diabetic retinopathy (DR) is the second leading cause of
blindness due to retinal degeneration, contributing to an
overall 4.8% blindness across the globe [1]. Clinically,
diabetic retinopathy is characterized as basement
membrane (BM) thickening, pericyte loss, endothelial
cell (EC) dysfunction, microaneurysms, microvascular
infarcts, and neovascularization in a patient with dia-
betic retinopathy [2,3]. Localized hypoxia has been
implicated in this process, which can eventually lead to
blindness. Although good glycemic control is considered
t ob eam a i n s t a yi np r e v e n t i n gt h ev i s i o nl o s s ,s o m e
patients with poor glycemic control do not develop reti-
nopathy. This is well documented in the Diabetes
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ted Kingdom Prospective Diabetes Study (UKPDS) [4,5].
Several bio-chemical pathways have been proposed to
mediate the pathogenesis of DR. These include polyol
accumulation, formation of advanced glycation end pro-
ducts (AGEs), oxidative stress, activation of protein
kinase C, upregulation of matrix metalloproteinases, ela-
boration of growth factors and secretion of adhesion
molecules [6,7]. Genetic as well as environmental factors
may play a crucial role in understanding the differential
susceptibility to DR. To date, markers at four chromoso-
mal loci have been linked with DR. By multipoint
sib-pair analysis, loci on chromosomes 3 and 9 showed
suggestive evidence for linkage to DR in American Pima
Indians with type 2 diabetes yielding lod scores of 1.36
and 1.46 respectively [8]. Two other recent studies also
suggested loci on chromosomes 1 and 3, and 12 with
suggestive support for a number of additional loci for
DR in Mexican Americans [9,10].
DR shows a complex inheritance pattern, and genetic
association studies are often used to identify the genetic
factors influencing its development. In this context,
polymorphic markers in or near several genes including
aldose reductase (AKR1B1), the receptor for AGE
(advanced glycation end products, RAGE), vascular
endothelial growth factor (VEGF), intercellular adhesion
molecule 1 (ICAM-1), pigment epithelium derived factor
(PEDF), hemochromatosis (HFE), and alpha2beta1 integ-
rin have been identified as being associated with DR
[11-17]. However, with the exception of VEGF, eNOS
(endothelial nitric oxide synthase), IGF (insulin like
growth factor), AKR1B1 and RAGE, detailed investiga-
tions of most of these associations in the Indian popula-
tion have not been carried out [13,18,19,21,23].
Therefore, the present study aims to evaluate SNPs in
nine candidate genes previously reported to be asso-
ciated with DR, including the receptor for advanced gly-
cation end products (RAGE), pigment epithelium
derived factor (PEDF or SERPINF1), aldose reductase
(AKR1B1), erythropoietin (EPO), intercellular adhesion
molecule 1 (ICAM-1), hemochromatosis (HFE), high
temperature requirement A1 or serine peptidase
(HTRA1), Complement Factor H (CFH) and age related
maculopathy susceptibility 2 (ARMS2) to determine
whether alleles of these markers are associated with DR
in an Indian population.
Methods
This study protocol was approved by both the Institu-
tional Review board and Ethics Committee of Aravind
Eye Hospital, Madurai, Tamil Nadu, India and Institu-
tional Review board of the National Eye Institute
(NEI), NIH, Bethesda, Maryland. Patients were
r e c r u i t e df r o mt h eA r a v i n dE y eH o s p i t a la n di t sc l i n i c s
and the laboratory part of the study was carried out at
the NEI in accordance with the tenets of Declaration
of Helsinki.
Enrollment of cases and controls
Patients who had T2DM (as defined by age of onset
being later than 30 years of age) and exclusively used
oral hypoglycemic agents were enrolled for this study
from the patient population of the Aravind Eye Hospital
and its outlying clinics. The criteria for diagnosis of dia-
betes were random blood sugars over 150 mgs% and
HbA1C over 6%. A case-control design was used with
two groups of diabetic patients: an unrelated ethnically
matched group of patients with DR (n = 345) and a
similar group of DNR (n = 359) were ascertained for the
genetic association study. Patients with no signs of DR
coupled with T2DM of 12-17 years duration were
assigned to the DNR study group. Patients with prolif-
erative diabetic retinopathy (PDR) as defined by eyes
with definite neovascularization and/or vitreous/preret-
inal hemorrhages were included in the DR study group.
Other patient details such as age, gender, body weight,
duration of diabetes, family history of diabetes, other
systemic illness, and treatment details were also docu-
mented (Table 1). They are essentially similar, although
the mean duration of diabetes was slightly longer in the
DNR individuals in enrollment group 2 (12 vs. 14
years). While the mean random blood sugars were
slightly higher in the DR than DNR groups (212 vs. 188
and 222 vs. 102 respectively), the HbA1C values were
similar (6.4 vs. 6.4 and 7.6 vs. 7.0 respectively). Statisti-
cally, the only significant differences in clinical charac-
teristics between the DR and DNR groups overall were
the percentage males (P = 0.05) and blood urea nitrogen
(P = 0.002).
All patients were subjected to a clinical evaluation
comprising a fundus examination by a binocular indirect
ophthalmoscope and a slit lamp biomicroscopic exami-
nation with a 90 D lens in the retina clinic of Aravind
Eye Hospital, Madurai, India. In addition, all patients
underwent 5-field 50° color fundus photography.
The second (confirmatory) group of patients and control
individuals including DR (n = 100) and DNR (n = 90) were
similarly recruited through the Aravind Eye Hospital and
its clinics and met the same diagnostic criteria as the first
(exploratory) group. Ascertainment and diagnosis of
patients seen at the Medical Research Foundation, Sankara
Nethralaya in Chennai, India were described previously in
detail [21]. Briefly, consecutive unrelated type II diabetic
patients seen at the Sankara Nethralaya were tested for
blood glucose and glycosylated Hb levels and a medical
history including their sex, weight, duration and treatment
of diabetes. Enrollment of cases and controls at the
Sankara Nethralaya Hospital has been previously described
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Aravind Eye Hospital [21].
Candidate gene and single nucleotide polymorphism
selection
A total of 14 SNPs and one dinucleotide repeat poly-
morphism in nine candidate gene regions were selected
for the present study. These genes were all reported to
be associated with DR in at least one population or are
logical candidate genes based on the current under-
standing of the pathogenesis of DR. The selected SNPs
are in the promoter region, 5’UTR region, or coding
regions of candidate genes. The primers for selected
SNPs and their corresponding genes are listed (Table
S1, Additional File 1). The primers were designed for
each SNP using Primer III, http://frodo.wi.mit.edu/,
except for a subset of SNPs (-374 T/A,-429 T/C and
rs2070600 in RAGE, rs35839483 in ALR, rs5498 in
ICAM-1, rs1136287, rs58697961, rs12150053 and
rs12948385 in PEDF and rs1617640 in EPO)f o rw h i c h
the primers were chosen from previous studies
[12,14,15,23,41].
Genotyping
Total genomic DNA was extracted from the peripheral
blood leukocytes by a salt precipitation method after
obtaining written informed consent from all the partici-
pants [22]. The SNPs in the RAGE (-374 T/A, -429 T/C
and rs2070600), PEDF (rs12150053, rs12948385,
rs58697961 and rs1136287), AKR1B1 (rs35839483), EPO
(rs1617640), HTRA1 (rs11200638), ICAM (rs5498), HFE
(rs1800562), CFH (rs1061170 and rs3753394) and
ARMS2/LOC387715 (rs10490924) were chosen on the
basis of their association with DR in previous studies.
SNPs were amplified by the polymerase chain reaction
(PCR), (Thermocycler 9700; Applied Biosystems, Inc.
[ABI], Foster City, CA). PCR reactions were performed
in 20-μL reaction volumes containing 10 mM Tris HCl
(pH 8.9), 50 mM KCl, 1.5 mM MgCl2,0 . 2μM of each
primer, 250 μM of each dNTP, 50 ng of genomic DNA,
and 0.5 units of Taq thermostable DNA polymerase
(ABI, Foster city, CA, USA). Cycling parameters were 5
minutes at 95°C, followed by 35 cycles of 30 seconds at
95°C, 30 seconds at the annealing temperature (Tm)o f
the primers (52°C-63°C, see Table S1, Additional File 1),
and 45 seconds to 1 minute at 72°C, with a final 10-
minute extension at 72°C.
Genotyping of rs1136287, rs58697961, rs12150053 and
rs12948385 in PEDF, rs11200638 in HTRA1, promoter
polymorphisms in RAGE (-429T/C, -374 T/A) were per-
formed by direct sequencing (BigDye terminator chem-
istry, ver. 3.1; ABI) using an automated DNA sequencer
(Prism 3130xl; ABI, Foster city, CA, USA). Genotyping
of rs1617640 in EPO was carried out by Taqman real
time PCR with an ABI 7900HT Fast Real-Time PCR
System (ABI, Foster city, CA, USA). Genotyping of the
ICAM-1 SNP rs5498 (K469E in exon 6), the HFE
SNP rs1800562 (C282Y in exon 3), the CFH SNPs
(rs1061170 and rs3753394), the ARMS2/LOC387715
gene SNP rs10490924 and rs2070600 in RAGE were car-
r i e do u tb yS N a P s h o tP C R( A B I 3 1 0 0G e n e t i cA n a l y z e r ,
ABI, Foster city, CA, USA) except for the cases studied
by Kumaramanickavel et al. [21] which were genotyped
by AluI RFLP analysis. Genotyping of rs35839483 in
AKR1B1 was performed using the primers described by
Kumaramanickavel et al. [23] with an M13 fluores-
cently-labeled tail primer followed by electrophoresis on
an ABI3130xl genetic analyzer (ABI, Foster city, CA,
USA). It should be noted that this technique offsets the
allele sizes by 19 bp. All genotypes were interpreted by
2 readers blinded to the sample phenotypes, and the
results were correlated and repeated if disagreements
Table 1 Clinical Characteristics of the study subjects
Patient enrollment 1 Patient enrollment 2 Kumaramanickavel et al.
DR
(n = 345)
DNR
(n = 359)
DR
(n = 100)
DNR
(n = 90)
DR
(n = 100)
DNR
(n = 100)
P (DR vs. DNR)*
Males (%) 70.0 58.0 56.7 57.6 79 64 0.05
Age (Years) (Mean± SD) 57 ± 9 59 ± 11 57 ± 8 58 ± 10 63 ± 7 62 ± 7 0.37
DM Duration ((Years) Mean ± SD) 14 ± 9 14 ± 9 12 ± 6 14 ± 5 17 ± 3 20 ± 5 0.42
Systolic Blood pressure (mmHg)
(Mean± SD)
137 ± 18 135 ± 18 134 ± 17 128 ± 13 154 ± 26 143 ± 21 0.28
Diastolic Blood Pressure (mmHg) (Mean± SD) 83 ± 7 82 ± 7 83 ± 10 80 ± 10 86 ± 12 81 ± 9 0.28
Random Blood
Sugar (mgs%)(Mean± SD)
212 ± 95 188 ± 85 222 ± 93 202 ± 80 N/A N/A 0.80
HbA1C (%) (Mean± SD) 6.4 ± 1.6 6.4 ± 1.2 7.6 ± 1.7 7.0 ± 1.7 8.9 ± 0.74 8.2 ± 4.8 0.09
Serum creatinine (mgs%) (Mean± SD) 1.0 ± 0.7 0.8 ± 0.2 1.0 ± 0.4 0.8 ± 0.3 N/A N/A 0.32
Blood urea (mgs%) (Mean± SD) 32 ± 14 25 ± 8 32 ± 11 27 ± 8 N/A N/A 0.002
N/A not available.
*trend test carried out on combined enrollment 1 and enrollment 2 data sets.
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HWE overall and for cases and controls with the excep-
tion of rs2070600, which shows slight deviation ( p >
0.001) only in the DR samples in the confirmatory data.
The confirmatory data set overall and DNR set as well
as all groups in the exploratory and combined ARA-
VIND data sets are in HWE for all markers tested.
Statistical Analysis
Chi-square, and Fisher exact tests were used to test the
allelic and genotypic associations of all the SNPs, and
Hardy-Weinberg equilibrium of each SNP in control as
well as in affected individuals was also examined using a
Χ
2 test, all as implemented in the Exemplar program
(Sapio Sciences, Baltimore, MD) or the Golden Helix
SVS software suite 7 (Golden Helix, Bozeman, MT).
Odds ratio, relative risk, and call rate were also calcu-
l a t e du s i n gt h es a m ep r o g r a m s .B e c a u s et h i si sad i r e c -
ted search of candidate genes with a presumed high
a priori probability of being associated a P-value < 0.05
was considered to be statistically significant. Corrections
for multiple testing were done by the Bonferroni
method where indicated. Association of clinical variables
with DR vs. DNR was carried out using the trend test
and calculated for the combined exploratory and confir-
matory data sets.
Results
The clinical characteristics of the study subjects are
shown in Table 1. In this study, patients with PDR as
defined by eyes with definite neovascularization and/or
vitreous/preretinal hemorrhages and more severe
hemorrhages were selected for the DR study group and
patients with no signs of DR coupled with type 2 dia-
betes of at least 12 years duration were selected for dia-
betic without retinopathy (DNR) study group. The
criteria for diagnosis of diabetes were random blood
sugars over 150 mgs% and HbA1C over 6%. The clinical
characteristics such as random blood sugars, HbA1C,
blood pressure, and duration of diabetes were essentially
similar in both groups, although the DR and DNR
exploratory groups both had somewhat longer duration
of diabetes in the report by Kumaramanickavel et al.
[21] than the confirmatory groups (17 and 20 vs. 14 and
14 years, respectively). Of the clinical characteristic
recorded only percentage males (P = 0.05) and blood
urea nitrogen (P = 0.002) were significantly associated
with DR. None of the clinical characteristics other than
DR were associated with any tested genotypes.
Among the 15 SNPs studied, only one, rs2070600
( G > A )i ne x o n3o fRAGE, which leads to a change of
amino acid glycine to serine at codon 82 displays signifi-
cant association with DR in the initial screening group
(Table 2). The G allele (P = 0.016), the homozygous GG
(P = 0.012), and the heterozygous GA (P-0.011) geno-
types are significantly associated with DR. Individuals
with the homozygous GG genotype of this SNP have
1.78 times higher risk of developing DR (OR = 1.78:
95% CI-1.13 - 2.82). A dominant model also shows asso-
ciation with DR (P = 0.012, Table 3), with the A allele in
either heterozygous of homozygous state giving an odds
ratio (OR) = 0.56 with 95% CI = 0.35 - 0.89. In contrast,
the other RAGE gene polymorphisms tested, -374 T/A
and -429 T/C, do not show any significant association
in this population. No other SNPs previously reported
to show association could be confirmed in this popula-
tion, with the possible exceptions of rs11200638 (G>A)
in HTRA1 and the LOC387715 SNP rs10490924, which
show marginally significant associations with DR (allelic
P = 0.055 and P = 0.07, respectively).
When association of rs2070600 is tested in the confir-
matory group the association is confirmed. Although the
allelic association test gives only a suggestive P = 0.068
(A allele OR = 0.54: 95% CI = 0.38 - 0.76), the whole
SNP P = 0.035 and a dominant model for the A allele
gives a P = 0.032 with an OR = 0.34 (95% CI = 0.13 -
0.94). Combining the two groups for analysis continues
to show significant association of rs2070600 with DR
(allelic P < 0.003). Similarly, the genotypic test
(P = 0.003), the dominant model (P = 0.0013, OR = 0.51,
95% CI = 0.34 - 0.82) and the additive model (P = 0.003)
all show significant association (Table 4).
The RAGE gene was selected as a candidate based on
previous analysis showing association in an Indian popu-
lation by Kumaramanickavel et al [21]. Because of the
ethnic and clinical similarities between the ARAVIND
and Sankara Nethralaya study populations (Table 1) and
because they represented the only two studies examin-
ing RAGE gene polymorphisms in the Indian popula-
tion, we decided to combine data from the two studies
in a single analysis. It was noted that our results for the
RAGE gene were remarkably similar to those reported
by Kumaramanickavel et al. [21] with major allele fre-
quencies of .95 vs. .95 and .92 vs. .89 for the DR and
DNR groups, respectively. The combined results once
more confirmed association of the G allele with DR:
allelic P < 0.0003 with the A allele OR = 0.54 (0.38 -
0.76). The whole SNP association is also significant with
a P = 0.0003, as are the results of analysis under specific
models with the A allele dominant P = 0.00011 with an
OR = 0.49 (95% CI = 0.34 - 0.7) and the additive model
P = 0.00047 (Table 4).
None of the remaining SNPs, including, four SNPs
rs1136287 (C/T), rs58697961 (G/A), rs12150053 (T/C)
and rs12948385 (G/A) in the PEDF gene, rs1617640
(G/T) in EPO, rs1800562 (G/A) in HFE, rs5498 (A/G) in
ICAM, rs1061170 and rs3753394 in CFH, rs10490924 in
ARMS2/LOC387715 and rs35839483 (CA)n in AKR1B1
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rs1800562 (G/A) in HFE was found not to be poly-
morphic in the study groups. Additionally, 12 alleles 138
bps-162 bps in rs35839483 (CA)n were identified. The
allele frequencies of the AKR1B1 (CA)n dinucleotide
repeat polymorphism are given in Table 5. None of the
alleles show significant association with DR in this
population.
Discussion
The present study evaluates the potential association of
fifteen polymorphisms in nine previously identified DR
candidate genes with type 2 diabetes patients in a South
Indian population. In this case-controlled study only
one SNP, rs2070600 in the RAGE gene, could be shown
to be significantly associated with retinopathy in the
presence of DR. Because of the relatively small number
Table 2 Allele and Genotype distribution of Nine candidate gene polymorphisms in the study
Gene SNP Allele DR DNR Odds ratio
(95% CI)
P Genotype DR
(n = 345)
DNR
(n = 359)
Odds ratio
(95% CI)^
P
RAGE (-374 T/A) T 98.10% 98.52% 0.77 (0.27-2.15) 0.62 TT 96.21% 97.05% 0.76 (0.27-2.13) 0.62
A 1.89% 1.48% TA 3.79% 2.95% 1.29 (0.46-3.63) 0.62
(- 429T/C) T 86.26% 83.76% 1.22 (0.84-1.76) 0.29 TT 74.88% 71.31% 1.19 (0.78-1.82) 0.39
C 13.74% 16.24% TC 22.75% 24.89% 0.88 (0.57-1.37) 0.59
CC 2.37% 3.80% 0.61 (0.20-1.86) 0.38
rs2070600 G 95.1% 91.9% 1.7 (1.1-2.6) 0.016* GG 90.4% 84.1% 1.78 (1.13- 2.82) 0.012*
A 4.9% 8.1% GA 9.3% 15.6% 0.55 (0.35-0.88) 0.011*
AA 0.3% 0.3% 1.04 (0.06 -16.7) 0.97*
PEDF rs12150053 T 77.86% 76.06% 1.10 (0.80-1.51) 0.52 TT 60.95% 58.12% 1.12 (0.76 -1.64) 0.54
C 22.14% 23.94% TC 33.81% 35.90% 0.91 (0.61-1.34) 0.64
CC 5.24% 5.98% 1.04 (0.06-1.95) 0.73
rs12948385 G 78.33% 80.17% 0.89 (0.64-1.23) 0.49 GG 62.38% 66.67% 0.82 (0.56-1.22) 0.34
A 21.67% 19.83% GA 31.90% 27% 1.26 (0.84-1.90) 0.25
AA 5.71% 6.33% 0.89 (0.40-1.96) 0.78
rs58697961 G 50.47% 51.90% 0.94 (0.72-1.22) 0.67 GG 27.01% 26.58% 1.02 (0.67-1.55) 0.91
A 49.53% 48.10% GA 46.92% 50.63% 0.86 (0.59-1.24) 0.43
AA 26.07% 22.78% 1.19 (0.77-1.84) 0.41
rs1136287 C 58.17% 54.03% 1.18 (0.90-1.54) 0.21 CC 34.13% 28.40% 1.30 (0.87-1.95) 0.19
T 41.83% 45.97% CT 48.08% 51.27% 0.88 (0.60-1.27) 0.5
TT 17.79% 20.33% 0.84 (0.52-1.36) 0.49
HTRA1 rs11200638 G 61.7% 70% 0.68 (0.45-1.01) 0.055 GG 39.34% 47.68% 0.64 (0.37-1.1) 0.11
A 38.3% 30.0% GA 46.92% 43.04% 1.18 (0.69-2.04) 0.53
AA 13.74% 9.28% 1.86 (0.8-4.3) 0.14
EPO rs1617640 G 67.30% 67.72% 0.98 (0.74 -1.29) 0.89 GG 43.60% 43.88% 0.98 (0.68-1.43) 0.95
T 32.70% 32.28% GT 47.39% 47.68% 0.98 (0.68-1.43) 0.95
TT 9% 8.44% 1.07 (0.55-2.07) 0.83
ICAM rs5498 A 53.42% 51.91% 1.06 (0.81-1.39) 0.66 AA 30% 27.66% 1.12 (0.73-1.70) 0.59
G 46.58% 48.08% AG 46.84% 48.51% 0.93 (0.63-1.37) 0.73
GG 23.16% 23.83% 0.96 (0.61-1.51) 0.87
CFH rs3753394 T 72.03% 69.49% 1.13 (0.83-1.53) 0.42 TT 55.36% 49.15% 1.28 (0.86-1.89) 0.21
C 27.97% 30.51% CT 33.33% 40.68% 0.72 (0.48-1.09) 0.12
CC 11.30% 10.17% 1.12 (0.60-2.10) 0.71
rs1061170 C 69.86% 72.25% 0.89 (0.66 - 1.19) 0.43 CC 48.33% 50% 0.93 (0.64-1.35) 0.72
T 30.14% 27.75% CT 43.06% 44.49% 0.94 (0.64-1.37) 0.76
TT 8.61% 5.50% 1.61 (0.77-3.38) 0.19
LOC387715 rs10490924 T 62.57% 68.43% 0.77 (0.57 - 1.02) 0.07 TT 38.55% 47.03% 0.70 (0.47 - 1.04) 0.08
G 37.43% 31.57% TG 48.04% 42.80% 1.23 (0.83 - 1.82) 0.28
GG 13.41% 10.17% 1.36 (0.74 - 2.49) 0.3
Chi-square test was used to compare the genotype and allele frequencies between cases and controls.
The SNPs are in Hardy-weinberg equilibrium.
*P-Value < 0.05 is considered to be statistically significant.
^The odds ratio for one genotype was calculated against the other two genotypes combined.
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necessarily exclude the possibility of alleles of the
remaining SNPs showing some association with DR,
especially those in HTRA1 and LOC387715. However, it
is unlikely that the level of association would be greater
than the 95% confidence limits of the odds ratios shown
in Table 3, which are generally less than 1.5 for allelic
association with the exception of the RAGE related
SNPs, and less than 2-2.5 for the genotype odds ratios.
Finally, it is possible that associations seen in other
populations might not be present in southern Indians
because of different population histories, which could
alter haplotype block structure and thus non-causative
allelic association, and possibly differing genetic and
environmental contributions to the disease risk in
various ethnic and geographic groups. In addition, this
study did not address the use of oral hypoglycemic
agents on the development of DR directly. However,
since the main effects of these agents would be expected
to result from their enhancement of glycemic control, to
some extent one might expect their effects to be
reflected in the fasting blood glucose and HbA1C levels,
which were similar in the DR and DNR subjects.
RAGE gene polymorphisms are attractive candidates to
influence DR because of pathophysiological data correlat-
ing retinopathy and advanced glycation end products
(AGEs). RAGE, which maps to chromosome 6p21.3, is a
member of the immunoglobulin super family. AGEs
result from the non-enzymatic glycation of proteins and
lipids. They are found at increased levels in diabetes and
Table 3 Analysis of RAGE under various models in the exploratory and confirmatory sets
Gene SNP Allele DR DNR Odds ratio
(95% CI)
P Model Odds ratio
(95% CI)
P
RAGE rs2070600 G 95.1% 91.9% 1.7 (1.1 -2.6) 0.016
2 SNP 0.04
2
A 4.9% 8.1% 0.59 (0.38-0.91) Dominant OR = 0.56 (0.35 - 0.89)
1 0.012
2
Additive R = -0.091 0.016
3
1(AA,AG)/AA.
2c
2, P-Value < 0.05 is considered to be statistically significant.
3Trend, P-Value < 0.05 is considered to be statistically significant.
Genotype and allele frequencies of RAGE in the confirmatory set
Gene SNP Allele DR DNR Odds ratio
(95% CI)
P Model Odds ratio/R
(95% CI)
P
RAGE rs2070600 G 96.5% 92.2% 1.78 (1.22 -2.60) 0.068 SNP 0.035
2
A 3.5% 7.8% 0.54 (0.38-0.76) Dominant OR = 0.34 (0.13 - 0.94)
1 0.032
2
Additive A R = -0.129 0.07
3
*includes the exploratory, confirmatory sets and that of Kumaramanickavel et al.
1(AA,AG)/AA.
2c
2, P-Value < 0.05 is considered to be statistically significant.
3Trend, P-Value < 0.05 is considered to be statistically significant (not corrected for multiple testing).
Table 4 Analysis of combined sets under various models
Genotype and allele frequencies of RAGE gene polymorphism rs2070600 in the exploratory and confirmatory sets combined
Gene SNP Allele DR DNR Odds ratio
(95% CI)
P Model Odds ratio
(95% CI)
P
RAGE rs2070600 G 95.4% 92% 1.8 (1.2 -2.7) 0.003
2 SNP 0.003
2
A 4.6% 8% 0.55 (0.37-0.82) Dominant 0.51 (0.34 - 0.77)
1 0.0013
2
Additive R = -0.0997 0.003
3
Genotype and allele frequencies of RAGE in all sets combined*
Gene SNP Allele DR DNR Odds ratio
(95% CI)
P Model Odds ratio/R
(95% CI)
P
RAGE rs2070600 G 95.2% 91.4% 1.78 (1.22 -2.60) 0.0003* SNP 0.0003
2
A 4.8% 8.6% 0.54 (0.38-0.76) Dominant 0.49 (0.34 - 0.70)
1 0.00011
2
Additive A R = -0.10548 0.00047
3
*includes the exploratory, confirmatory sets and that of Kumaramanickavel et al.
1(AA,AG)/AA.
2c
2, P-Value < 0.05 is considered to be statistically significant.
3Trend, P-Value < 0.05 is considered to be statistically significant (not corrected for multiple testing).
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Page 6 of 9can lead to increased oxidative stress and receptor-
mediated activation and secretion of various cytokines
[24,25]. Accumulation of AGEs has been suggested to
contribute to vasculopathy by increasing retinal endothe-
lial cell permeability [26]. Specific AGE-binding receptors
include the AGE-receptor complex, the macrophage sca-
venger receptors, and the receptor for AGE (RAGE). A
Gly82Ser polymorphism in RAGE is potentially interest-
ing since it occurs at a predicted N-linked glycosylation
motif in the AGE binding site, thereby influencing AGE-
RAGE interactions [12]. Kumaramanickavel et al. [21]
previously reported that this polymorphism is associated
with decreased risk for the development of DR in a
Southern Indian population essentially similar to the one
studied here. However, additional studies investigating
the same locus did not show significant association for
this polymorphism in Chinese and Japanese populations
[20,27], and a recent study showed association of the A
allele (serine) with DR in a Han Chinese population [28].
Association of the opposite allele of a polymorphism with
disease has been reported before, and an additional
example with an elegant theoretical analysis of possible
causes for this has been presented by Lin et al. [29,30].
As also suggested by Zhang et al. [28] in their report, this
might represent either different molecular pathogenesis
of the disease in the two populations or simply a different
population history resulting in different haplotype struc-
ture of the associated region. A particularly interesting
example is that of the LOXL1 polymorphisms rs3825942
and rs1048661, which are in linkage disequilibrium and
both show association with exfoliative glaucoma (XFG)
[31,32]. While the G allele of rs3825942 is associated
with XFG in both Caucasian and Japanese populations,
the G allele of rs1048661 (GG haplotype of rs1048661
and rs3825942) is associated with XFG in Caucasians but
the T allele (TG haplotype of rs1048661 and rs3825942)
is associated with XFG in Japanese.
Our study supports association of the 82Gly allele and
DR (P = 0.0003) with an odds ratio of 0.54 (95% confi-
dence interval = 0.38 - 0.76) for the 82Ser (A) allele in a
southern Indian population. Although the AA genotype
appears to have an increased OR in the exploratory
cohort (1.04, Table 2), this is due to the presence of a
single AA individual in both the DR and DNR groups
and probably represents a chance variation. Overall, the
risk for DR decreases with the number of 82Ser (A)
alleles, with both the additive model and dominant
models supporting association. This supports the origi-
nal findings of Kumaramanickavel et al. that 82Ser is a
protective allele for diabetic retinopathy in the Indian
population, and the similarities between the study popu-
lations in terms of ethnic origin and clinical criteria sug-
gested that results from the subjects of both studies
might be combined in a single analysis [21,33]. The
individuals in the study by Kumaramanickavel et al. [21]
were slightly older (63 years vs. 57 years average), had a
slightly longer history of diabetes (18 years vs. 14 years
average) and had somewhat higher HbA1C values (8.5
vs. 6.4 average). However, the similarities in the diagnos-
tic and exclusion criteria and particularly the Indian eth-
nic composition of both groups allowed a combined
analysis. The combined analysis was consistent with the
results of subjects recruited from both hospitals, giving
a similar odds ratios for the G allele (1.8 vs. 1.7), in the
combined and ARAVIND patients respectively. The
combined results, however, showed increased signifi-
cance, with improvements in both the allelic (0.0003 vs.
0.003) whole SNP genotypic (0.0003 vs. 0.003) dominant
(0.00011 vs 0.0013) and additive (0.00047 vs. 0.003)
p-values in the combined and Aravind groups respectively.
While we have not included a Bonferroni correction
directly because of uncertainty about the a priori likeli-
hood of each locus being true, a Bonferroni correction
for multiple testing considering tests for 15 markers
were performed might be a P < 0.0033, which is met in
the combined ARAVIND and the final combined data
sets.
In contrast to the results with rs2070600, neither the
-374 T/A SNP nor the -429 T/C SNP in RAGE were
found to be associated with DR, even though this asso-
ciation had been reported in the British population [34].
This might reflect population differences in the patho-
genesis of DR in the Indian and other populations, but
might also be a reflection of the relatively low minor
allele frequencies in the Indian population, as the 95%
confidence intervals for these SNPs, and especially -374
T/A, are very wide.
A putative transcription factor binding site of the
HTRA1 gene in the 10q26 region was shown to confer
significant risk for choroidal neovascularization in
age related macular degeneration (AMD) and SNPs
Table 5 Allele frequencies of ALR2 (CA)n polymorphism
Allele DR (n =
422)
DNR (n =
474)
Odds Ratio (95%
CI)
P-Value
138 0 3 (0.63%) ∞ 0.1<p<0.25
140 4 (0.94%) 8(1.68%) 0.55 (0.16 -1.86) 0.5<p<0.25
142 1 (0.23%) 0 ∞ 0.5<p<0.25
146 3 (0.71%) 0 ∞ 0.1<p<0.05
148 20 (4.73%) 16 (3.37%) 1.424 (0.72 -2.78) 0.5<p<0.25
150 73 (17.29%) 65 (13.71%) 1.316 (0.91 -1.89) 0.75<p<0.5
152 189 (44.78%) 216 (45.56%) 0.96 (0.74 -1.26) 0.9<p<0.75
154 55 (13.03%) 65 (13.71%) 0.94 (0.64 -1.38) 0.9<p<0.75
156 41 (9.71%) 43 (9.07%) 1.07 (0.68 -1.69) 0.9<p<0.75
158 23 (5.45%) 39 (8.22%) 0.64 (0.37 -1.09) 0.1<p<0.25
160 11 (2.60%) 19 (4%) 0.64 (0.30 -1.36) 0.1<p<0.25
162 2 (0.47%) 0 ∞ 0.1<p<0.25
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Page 7 of 9rs1061170, rs3753394 in CFH and rs10490924 in
ARMS2/LOC387715 showed significant association
[35-40]. Because neovascularization is common to both
A M Da n dD R ,w eh y p o t h e s i z e dt h a tt h e s eg e n e sm a y
p l a yar o l ei nD R .T ot h eb e s to fo u rk n o w l e d g e ,t h i si s
the first report correlating the association of these SNPs
with DR (however, our results indicate only marginal
significance of the SNP rs11200638 in HTRA1 gene
with DR).
We have attempted to avoid population substructure
in our study. However, it remains possible that the posi-
tive and negative results could potentially be due to
subtle population stratification and should be taken as
suggestive rather than definitive.
Conclusion
In conclusion, we are able to confirm association of the
G82S polymorphism of RAGE with diabetic retinopathy
in the population of southern India. We studied the
association of SNPs rs11200638 in the HTRA1 gene,
rs1061170, rs3753394 in CFH and rs10490924 in
ARMS2/LOC387715 with DR for the first time. Our
findings suggest that these three polymorphisms may
not be associated with DR in the southern Indian popu-
lation. Our data also strongly suggest that patients with
the serine allele of the Gly82Ser (rs2070600) polymorph-
ism in the RAGE gene show a decreased risk for diabetic
retinopathy in the Indian population, although associa-
tion of this allele with DR in a Chinese population sug-
gests that this might represent linkage disequilibrium
with a nearby causative rather than implying that glyca-
tion at this site plays a directly causative role in the
development of diabetic retinopathy.
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